Table 1.
Prevalence of autoantibodies in different disease groups.
| IIM MSA |
Sensitivity n pos, % pos (95% CI) |
Specificity n pos, % pos (95% CI |
Odds Ratio (95% CI) |
|---|---|---|---|
| Jo-1 | 52/264 19.7 (15.3–24.9) |
0/200 100.0 (98.1–100.0) |
98.1 (6.0–1600.3) |
| PL-7 | 7/264 2.7 (1.3–5.4) |
0/200 100.0 (98.1–100.0) |
27.2 (0.3–2329.2) |
| PL-12 | 5/264 1.9 (0.8–4.4) |
1/200 99.5 (97.2–99.9) |
3.8 (0.6–25.0) |
| EJ | 3/264 1.1 (0.4–3.3) |
0/200 100.0 (98.1–100.0) |
11.5 (0.1–1066.4) |
| Mi-2 | 19/264 7.2 (4.7–11.0) |
0/200 100.0 (98.1–100.0) |
77.6 (0.9–6377.9) |
| NXP2 | 8/264 3.0 (1.5–5.9) |
2/200 99.0 (96.4–99.7) |
3.1 (0.7–13.0) |
| SAE | 10/264 3.8 (2.1–6.8) |
0/200 100.0 (98.1–100.0) |
39.4 (0.5–3304.9) |
| TIF1γ | 39/264 15.5 (11.0–19.6) |
1/200 99.5 (97.2–99.9) |
34.5 (5.9–200.6) |
| MDA5 | 22/264 8.3 (5.6–12.3) |
3/200 98.5 (95.7–99.5) |
6.0 (1.9–19.0) |
| HMGCR | 16/264 6.1 (1.6–23.5) |
2/200 99.0 (96.4–99.7) |
6.4 (1.6–25.2) |
| SRP | 5/264 1.9 (0.8–4.4) |
3/200 98.5 (95.7–99.5) |
1.3 (0.3–4.9) |
Abbreviations: IIM = idiopathic inflammatory myopathies; MSA = myositis-specific antibodies.